健脾理气方药物血清对人肝癌HepG2细胞株干预的机制研究
|
摘要
目的:肝癌是原发于肝细胞或肝内胆管上皮细胞的恶性肿瘤之一。在肿瘤的发病中,原发性肝癌在我国男性居第三位,女性居第四位.中国每年约有12万人死于肝癌。由于其恶性度极高,现有的治疗方法均达不到满意的效果,寻找有效的治疗药物和方法是目前肝癌治疗的一项重要课题。越来越多的证据表明,中医药在防治肝癌的发病及改善患者的免疫状态、提高患者生存率方面有其独特疗效。许多中药具有诱导细胞凋亡(APO)、影响DNA、RNA合成及保持相关酶活性的作用。健脾理气方是临床常用验方,探讨健脾理气方对肝癌作用的机制,为中药治疗肝癌提供可靠的依据已成为当务之急。
方法:以中药血清学方法测定健脾理气方药物血清对人肝癌HepG2细胞株作用的最佳量效、时效点;以倒置相差显微镜、光镜、透射电镜观察经健脾理气方药物血清处理后的人肝癌HepG2细胞株的形态学变化,以流式细胞化学方法研究人肝癌HepG2细胞株在健脾理气方药物血清的影响下细胞形态学变化及联合DNA琼脂凝胶电泳法检测细胞凋亡典型的梯状带分析;以Western blot法测定经药物血清处理后的人肝癌HepG2细胞株P53、bcl-2基因的蛋白表达水平;以酶细胞化学染色方法观察健脾理气方药物血清对人肝癌HepG2细胞株Mg2+-ATP酶、G-6-P酶活性的影响。
结果:以不同时相药物血清作用人肝癌HepG2细胞株后,除2t-1h组药物血清未见明显增殖抑制作用,其余各组均表现明显抑制作用,以3t-2h组药物血清抑制作用最好,抑制率达54.81%,以不同浓度药物血清作用24h、48h后,除中药中小剂量药物血清作用24h组外,其余各组均表现明显的抑制作用,以中药大剂量药物血清作用48h组抑制作用最佳,抑制率达53.96%;倒置相差显微镜下,经药物血清处理后的HepG2细胞彼此失去连结,收缩变圆,贴壁能力减弱,易从培养瓶上脱落下来,光镜下观察药物血清作用后,细胞收缩变圆,部分细胞出现固缩,细胞核染色质聚集,断裂成块状、颗粒状或月形小体,细胞形态呈凋亡特征性改变,电镜下,经药物血清处理的HepG2细胞,表面微绒毛减少甚至消失,核染色质浓集,胞质内有空泡形成,细胞膜起皱呈出芽状,可见凋亡小体形成,以DNA琼脂凝胶电泳法检测,健脾理气方药物血清能诱导人肝癌HepG2细胞形成凝胶电泳特异梯状带,以流式细胞化学方法定量分析健脾理气方药物血清作用24、48h,在G1峰前出现的明显凋亡峰(Ap峰),测得凋亡细胞占整个细胞群分别为1.8%和8.2%;人肝癌HepG2细胞株经药物血清处理前后蛋白表达Western-Blot结果显示,P53蛋白表达水平增高、bcl-2蛋白表达水平降低;经健脾理气方药物血清处理后,光镜下见用药组人肝癌HepG2细胞株Mg2+-ATPase和G-6-Pase酶反应颗粒较正常变小,数量减少,密度减低,酶活性下降。
结论:
1.健脾理气方药物血清对人肝癌HepG2细胞株体外具有抑制肿瘤细胞增殖的作用,作用的最佳量效、时效点为大剂量,3t-2h;
2.健脾理气方药物血清对人肝癌HepG2细胞株具有诱导细胞凋亡的作用;
3.健脾理气方药物血清可上调人肝癌HepG2细胞株P53基因的蛋白表达水平,下调bcl-2基因的蛋白表达水平;
4.健脾理气方药物血清具有降低人肝癌HepG2细胞株Mg2+-ATP酶和G-6-P酶的活性的作用。
Purpose: Liver cancer is one of the malignant tumors, which is due to liver cells or intrahepatic bile duct epithelial cells. In all kinds of tumour, the incidence of PHC is the third of the male in China, the fourth of female. There are over 120 thousand persons dying of liver cancer in China every year. Due to the high malignancy, current therapy methods are not of satisfied effect. To search active drugs and methods is an important program to cure liver cancer. More and more truths prove that the traditional Chinese medicine has especially curative effect on preventing from the invasions of liver cancer, improving sufferers’immune and raising the survival rate. Lots of herbs can induce APO, influence the synthesis of DNA and RNA and hold the activity of correlated enzyme. Jianpi Liqi herbs are commonly applied in clinic. It is necessary to research the mechanism of the herbs and supply reliable evidence to treat liver cancer.
Method: With the serological method, to determine the best quant potency and time limitation of effecting human liver cancer HepG2 cell strain by drug serum of Jianpi Liqi herbs. With inverted phase contrast microscope, light microscope and transmission electron microscope, to observe the liver cancer HepG2 cell strain’s morphological change after dealing by drug serum; to determine the liver cancer HepG2 cell strain gene P53 and bc1-2’s express level; to observe the activity of Enzyme Mg2+-ATP and G-6-P through enzyme cytochemical staining method.
Result: With different phase drug serum, inhibitory action was not obviously seen in the liver cancer HepG2 cell strain except Group 2t-1h. Other groups were opposite. Group 3t-2h was the best, inhibition ratio approaching to 54.81%. In different concentration drug serum, within 24 hours and 48 hours, the effect of each group was obvious but in low concentration within 24h. In all the groups, the high concentration within 48h was the best, inhibition ratio 53.96%. Under the inverted phase contrast microscope, the HepG2 blanked and shrink to round. Their adherent abitity was attenuated and the cells easily ablated from the culture flasks. Under the light microscope, the cells shrink to round and part cells pyknosised. The nuclear chromatins aggregated, collapsing to massive, granulo- or selene corpuscles. The cells were to die. Under the electron microscope , the surface microvilli of HepG2 decreased even disappeared. The nuclear chromatins enriched , intracytoplasm cavitating. The cell membranes corrugated as buds, apoptotic body forming could be seen clearly. With the DNA abstraction of cells and agarose gel electrophoresis,there was a“ladder strip”appearance. Collected the cells treated with drug serum about 24h,48h,there is a apoptotic peak obviously. inhibition ratio approaching to 1.8% and 8.2%.Westerm-blot result displayed that the increase of P53 express level and the decrease of bc1-2. Under the light microscope, after Mg2+-ATPase and G-6-Pase reacted, it was seen that the grains were shrinking and decreasing comparing to normal, and the density was degraded.
Conclusion: The effect of drug serum of Jianpi Liqi herbs on human liver cancer HepG2 cell strain was obvious. The best effective dose and time limitation is 3t-2h, in high concentration. There was manifest generation inhibitory action of the drug serum, which could induce the apoptosis, which also up-regulate the proternum express level of human liver cancer HepG2 cell strain Gene P53 but down-regulate bc1-2, and restrain the activity of HepG2 cell strain Mg2+-ATPase、G-6-Pase.
方法:以中药血清学方法测定健脾理气方药物血清对人肝癌HepG2细胞株作用的最佳量效、时效点;以倒置相差显微镜、光镜、透射电镜观察经健脾理气方药物血清处理后的人肝癌HepG2细胞株的形态学变化,以流式细胞化学方法研究人肝癌HepG2细胞株在健脾理气方药物血清的影响下细胞形态学变化及联合DNA琼脂凝胶电泳法检测细胞凋亡典型的梯状带分析;以Western blot法测定经药物血清处理后的人肝癌HepG2细胞株P53、bcl-2基因的蛋白表达水平;以酶细胞化学染色方法观察健脾理气方药物血清对人肝癌HepG2细胞株Mg2+-ATP酶、G-6-P酶活性的影响。
结果:以不同时相药物血清作用人肝癌HepG2细胞株后,除2t-1h组药物血清未见明显增殖抑制作用,其余各组均表现明显抑制作用,以3t-2h组药物血清抑制作用最好,抑制率达54.81%,以不同浓度药物血清作用24h、48h后,除中药中小剂量药物血清作用24h组外,其余各组均表现明显的抑制作用,以中药大剂量药物血清作用48h组抑制作用最佳,抑制率达53.96%;倒置相差显微镜下,经药物血清处理后的HepG2细胞彼此失去连结,收缩变圆,贴壁能力减弱,易从培养瓶上脱落下来,光镜下观察药物血清作用后,细胞收缩变圆,部分细胞出现固缩,细胞核染色质聚集,断裂成块状、颗粒状或月形小体,细胞形态呈凋亡特征性改变,电镜下,经药物血清处理的HepG2细胞,表面微绒毛减少甚至消失,核染色质浓集,胞质内有空泡形成,细胞膜起皱呈出芽状,可见凋亡小体形成,以DNA琼脂凝胶电泳法检测,健脾理气方药物血清能诱导人肝癌HepG2细胞形成凝胶电泳特异梯状带,以流式细胞化学方法定量分析健脾理气方药物血清作用24、48h,在G1峰前出现的明显凋亡峰(Ap峰),测得凋亡细胞占整个细胞群分别为1.8%和8.2%;人肝癌HepG2细胞株经药物血清处理前后蛋白表达Western-Blot结果显示,P53蛋白表达水平增高、bcl-2蛋白表达水平降低;经健脾理气方药物血清处理后,光镜下见用药组人肝癌HepG2细胞株Mg2+-ATPase和G-6-Pase酶反应颗粒较正常变小,数量减少,密度减低,酶活性下降。
结论:
1.健脾理气方药物血清对人肝癌HepG2细胞株体外具有抑制肿瘤细胞增殖的作用,作用的最佳量效、时效点为大剂量,3t-2h;
2.健脾理气方药物血清对人肝癌HepG2细胞株具有诱导细胞凋亡的作用;
3.健脾理气方药物血清可上调人肝癌HepG2细胞株P53基因的蛋白表达水平,下调bcl-2基因的蛋白表达水平;
4.健脾理气方药物血清具有降低人肝癌HepG2细胞株Mg2+-ATP酶和G-6-P酶的活性的作用。
Purpose: Liver cancer is one of the malignant tumors, which is due to liver cells or intrahepatic bile duct epithelial cells. In all kinds of tumour, the incidence of PHC is the third of the male in China, the fourth of female. There are over 120 thousand persons dying of liver cancer in China every year. Due to the high malignancy, current therapy methods are not of satisfied effect. To search active drugs and methods is an important program to cure liver cancer. More and more truths prove that the traditional Chinese medicine has especially curative effect on preventing from the invasions of liver cancer, improving sufferers’immune and raising the survival rate. Lots of herbs can induce APO, influence the synthesis of DNA and RNA and hold the activity of correlated enzyme. Jianpi Liqi herbs are commonly applied in clinic. It is necessary to research the mechanism of the herbs and supply reliable evidence to treat liver cancer.
Method: With the serological method, to determine the best quant potency and time limitation of effecting human liver cancer HepG2 cell strain by drug serum of Jianpi Liqi herbs. With inverted phase contrast microscope, light microscope and transmission electron microscope, to observe the liver cancer HepG2 cell strain’s morphological change after dealing by drug serum; to determine the liver cancer HepG2 cell strain gene P53 and bc1-2’s express level; to observe the activity of Enzyme Mg2+-ATP and G-6-P through enzyme cytochemical staining method.
Result: With different phase drug serum, inhibitory action was not obviously seen in the liver cancer HepG2 cell strain except Group 2t-1h. Other groups were opposite. Group 3t-2h was the best, inhibition ratio approaching to 54.81%. In different concentration drug serum, within 24 hours and 48 hours, the effect of each group was obvious but in low concentration within 24h. In all the groups, the high concentration within 48h was the best, inhibition ratio 53.96%. Under the inverted phase contrast microscope, the HepG2 blanked and shrink to round. Their adherent abitity was attenuated and the cells easily ablated from the culture flasks. Under the light microscope, the cells shrink to round and part cells pyknosised. The nuclear chromatins aggregated, collapsing to massive, granulo- or selene corpuscles. The cells were to die. Under the electron microscope , the surface microvilli of HepG2 decreased even disappeared. The nuclear chromatins enriched , intracytoplasm cavitating. The cell membranes corrugated as buds, apoptotic body forming could be seen clearly. With the DNA abstraction of cells and agarose gel electrophoresis,there was a“ladder strip”appearance. Collected the cells treated with drug serum about 24h,48h,there is a apoptotic peak obviously. inhibition ratio approaching to 1.8% and 8.2%.Westerm-blot result displayed that the increase of P53 express level and the decrease of bc1-2. Under the light microscope, after Mg2+-ATPase and G-6-Pase reacted, it was seen that the grains were shrinking and decreasing comparing to normal, and the density was degraded.
Conclusion: The effect of drug serum of Jianpi Liqi herbs on human liver cancer HepG2 cell strain was obvious. The best effective dose and time limitation is 3t-2h, in high concentration. There was manifest generation inhibitory action of the drug serum, which could induce the apoptosis, which also up-regulate the proternum express level of human liver cancer HepG2 cell strain Gene P53 but down-regulate bc1-2, and restrain the activity of HepG2 cell strain Mg2+-ATPase、G-6-Pase.
引文
[1] Hiroko Iwama, Sakae Amagaya and Yukio Ogihara. Effect of shosaikoto, aJ apanese and Chinese herbal medicinal mixture, on the mitogentic activity of Lipopolysaccharide. A new pharmacological testing method. J Ethmopharmacol, 1987; 211: 45.
[2]田代真一.“血清药理学”と“血清药化学”——汉方の药理学かぃ始まつた药物血中浓度测定の新しぃ世界.TDM研究,1988;(5):54.
[3]吴水生,等.血清药理学研究中含药血清是否需灭活的探讨.[J]福建中医学院学报,2001,11(2):45.
[4]张德付.中药血清药理学方法在肿瘤研究中存在的主要问题及对策.[J]中医研究,2004,17(5)13.
[5]罗焕敏.关于“血清药理学”与“血浆药理学”.[J]中国药理学通报,2003,19(9):1075.
[6]陆慧晶.血清药理学研究中的若干问题探讨.[J]基层中药杂志,2000,14(3):51.
[7]刘平.关于血清药理学的若干思考.[J]中国中西医结合杂志,1995,19(5):263.
[8]王力倩,等.血清药理学方法研究探索.[J]中药药理与临床,1997,13(3):29.
[9]杨彦芳,王玉芹.中药复方血清药理学方法规范化探讨.[J]中国中西医结合杂志,2000,20(5):380.
[10]李仪奎.中药血清药理学实验方法的若干问题.[J]药新药与临床药理,1999,10(5):263.
[11]罗焕敏.关于“血清药理学”与“血浆药理学”.[J]中国药理学通报,2003,19(9):1075.
[12]程珠炉,洪浩.中药血清药理学研究方法的几点思考.[J]安徽中医学院学报,2001,20(2):531.
[13]王力倩,等.用中药血清药理学的方法观察苦参、仙鹤草的抗肿瘤作用.[J]中国中医药科技,1995,2(5):19.
[14]李秀荣,等.消瘤平移合剂含药血清对肝癌细胞H-7402细胞凋亡的实验研究.[J]中国中西医结合杂志,2001,21(9):684.
[15]王宁生.关于血清药理学的若干思考.[J]中国中西医结合杂志,1999,19(5):263.
[16]孟李,王宁生.含药血清的制备方法研究.[J]中药新药与临床药理,1999,10(5):290.
[17]程珠炉,洪浩.中药血清药理学研究方法几点思考.[J]安徽中医学院学报,2001,20(2):53.
[18]崔晓兰,等.中药复方血清药理研究方法学探讨.[J]中国实验方剂学杂志,1998,4(2):13.
[19]杨奎,等.中药血清药理学方法学研究给药方案的研究.[J]中药药理与临床,1999,15(3):43.
[20]吴健宇,等.补阳还五汤保护自由基损伤血管内皮细胞的血清药理实验方法的建立.[J]中药药理与临床,1999,15(1):4547.
[21] Srehan P,et al. New eolorimetric cytotoxicity assay for auticaneer-drug screening J of Nat Cancer Ins. 1990,82(13):1107.
[22]王青素,等.SRB显色法用于抗癌药物敏感性实验的研究.[J]科技通报,2000,16(2):104.
[23] Mosmann T. Rapid Colorimetric Assay for cellular Growth and Survival; Applecation to Proliferation and Cytotoxcity Assays .[J] Immunol Methods ,1983,65:55.
[24]李杰,刘玉琴.MTT法在肿瘤研究中的改良及应用进展.[J]中国肿瘤临床,1998,25(4):312.
[25]朱寿兴,等.肿瘤细胞体外药物敏感实验MTT法在实体肿瘤中的应用.[J]华西药学杂志,1998,13(3):154.
[26]曾庆华,等.MTT测定恶性肿瘤细胞对化疗药物敏感性.[J]中国普通外科杂志.2000,9(6):552.
[27] Tim Oo Khor,et al. Positive correlation between overexpression of phospho-BAD with phosphorylated Akt at Serine 473 but not threoning 308 in colorectal carcinoma. Cancer Letters,2004,210:139.
[28] Daveau M,et al. Hepatocyte growth factor;transforming growth factor alpha,and their receptors as combined markers of prognosis in hepatocellular carcinoma. [J] Mol Carcinog,2003,36(3):130.
[29]梁重峰,潘立群.中医药调控肿瘤细胞凋亡的研究进展.[J]甘肃中药,2005,18(3):47.
[30] Yano H,et al. The herbel medicine sho saikoto inbibit sprolifertion of cancer celling by inducing apolosis and arest at the G0/G1 phase. [J] Cancer Res,1994,54(2):448.
[31]孙震晓,等.去甲斑蝥素诱导人肝癌细胞的影响.[J]临床肝胆病杂志,1999,30(1):65.
[32]邸雅南,等.刺五加叶皂苷对肝癌细胞的影响[J] .临床肝胆病杂志,2000,6(2):104.
[33]杨雁,陈敏珠.黄芪总提取物诱导肝癌细胞凋亡及其作用机理.[J]中国药理学会通讯,2000,17(4):16.
[34]汤利华,等.槲皮素对肝癌HepG2细胞生长影响的体外研究.[J]中国药业,2007,16(15)11.
[35]樊光华,等.人参皂甙-Rh2诱导人肝癌Bel-7404细胞凋亡的作用.[J]实用癌症杂志,2003,18(1):16.
[36]钟志宏,等.丹参酮ⅡA抑制HepG2细胞生长及诱导其凋亡的实验研究.[J]中南大学学报,2007,32(1):99.
[37]徐学军,等.B-榄香烯诱导人肝癌细胞珠7721凋亡的研究.[J]第三军医大学学报,1999,21(4):268.
[38]刘剑伦,等.康莱特注射液诱导人肝癌细胞凋亡的研究.[J]实用癌症杂志,2001,16(4):343.
[39]邵红莲,等.大蒜素诱导人肝癌7402细胞凋亡.[J]解剖学报,2001,32(3):290.
[40]张天娥,等.鹤莲克癌灵对肝癌H22细胞周期及细胞凋亡的影响.[J]成都中医药大学学报,1999,9(5):25.
[41]韩克起,黄传继.扶正抗癌方对大鼠移植性肝癌病理形态及超微结构的影响.[J]中西医结合肝病杂志,1999,9(5):25.
[42]张丽红,等.益肠泰诱导CCL229人大肠癌细胞凋亡的形态学研究.[J]中国基层医药,2007,14(6):974.
[43] Shimizu H,et al. The conformationally flexible S9-S10 linke rregion in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 invivo. [J] Biol Chem,2002,277:28446.
[44] Leung KM,et al. The candidate tumor suppressor ING1b can stabilize p53 by disrupting the regulation of p53 by MDM2. Cancer Res,2002,62:4890.
[45] Kataoka H,et al. ING1 represses transcription by direct DNA binding and through effects on p53. Cancer Res,2003,3:5785.
[46] Power C,et al. Cellular apoptosis and organ injury insepsis:a review. Shock,2002,18(3): 197.
[47] Hainaut P,Pfeifer GP. Pattems of p53 G-T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. [J] Carcinogenesis,2001,22(3):367.
[48] Ltoh T,et al. Relationship between p53 overexpression and the proliferation activity in hepatoccllular carcinoma. [J] Int J Mol Med,2000,6(2):137.
[49] Xiao EH,et al. Effects of p53 on apoptosis and proliferation of hepatocellular carcinoma cells treated with transcatheter arterial chemoembolization. World J Gastroenterol, 2004,10(2):190.
[50] Brfssac B,et al. Abnormal structore and expression of p53 gene in human hepatoccllular carcinoma. [J] Proc Natl Acad Sci USA,1990,87(1):973.
[51] Kigawa J,et al. Effect of p53 gene transfer and cisplatin in a peritonit is carcinomatosa model with p53 deficient ovarian cancer cells. [J] Gynecol Oncol,2002,84(2):210.
[52] Shinoura N,et al. Cotransduction of Apafand caspase-9 highly enhances p53-mediated apoptosis in gliomas. [J] Br J Cancer,2002,86(4):587.
[53]张建中,等.凋亡调控基因Mcl-1和bcl-2在反应性及肿瘤性淋巴组织中的表达及其意义.[J]肿瘤防治杂志,2002,9(1):22-24,29.
[54] Chiu CT,et al. Expression of Bcl-2 family modulated through p53-dependent pathway in human hepatocel-lular carcinoma. [J] Dig Dis Sci,2003,48(6):670.
[55] Cleary ML,et al. Cloning and structure analysis of cDNA for bcl-2 and hybrid bcl-2 immunoglobulin transcripts resultion from the t(14;18) translocation . [J] Cell,1986,47:19.
[56] Shibata D,et al. Detection of specific t(14;18) chromosomal translocations in fixed tissue. [J] Human Pathol,1990,21:199.
[57] Weiss LM,et al. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. [J] N Engl J Med,1987,317:1185.
[58] Guo XZ,et al. Effect of bax,bcl-2 and bcl-xl on regulating apoptosis in tissues of normal liver and hepatocellular carcinoma. World J Gastroenterol,2002,8(6):1059.
[59] Chang YC,Xu YH. Expression of Bcl-2 inhibited Fas-mediated apoptosis in human hepatocellular carcinoma BEL-7404 cells. Cell Res,2000,10(3):233.
[60]郭琳琅,肖莎.应用原位杂交技术检测原发性肝癌组织中bcl-2基因断裂点.[J]实用癌症杂志,1998,13(4):255.
[61] Nakopoulou L,et al. Bcl-2 protein expression in acule and chroic hepatitis cirrhosis and hepatocellular carcinomal. [J] Pathol Res Prect,1999,195(1):19.
[62]王万忠,等.Bcl-2癌基因在肝肿瘤表达.[J]中华医学杂志,1996,76(6):470.
[63] Charlotte F,et al. Immunohistochemical detection of bcl-2 protein in normal and patholical human liver. [J] Am J Pathol,1994,144:460.
[64] Fiorentino M,et al. High levels of bcl-2 messenger RNA detected by in siiu hybridization in human hepatocellular and cholangiocellular carcinomas. [J] Diagn Mol Pathol,1999,8(4);189.
[65] Toschi E , et al. Wild-Type p53 gene transfer inhibits invasion and reduces matrix metalloproteinase-2 levels in p53-mutated human melanoma cells. [J] Invest Dermatol,2000,114:1188.
[66] Tadahisa S,et al. A poptosis induced by adenovirus-mediated p53 gene transfer in human glimna correlates with site-specific phosphorylation. [J] Cancer Res,2002,62:1069.
[67] Watanabe T,Sullenger BA. Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. Proc Natl Acid Sci USA,2000,97:8490.
[68]袁静.檞皮素抗肿瘤作用研究进展.[J]国外医学中医中药分册,1996,18(5):3.
[69]黄培春.中药复方“冬夏丸”体外对6株人肿瘤细胞系作用的研究.[J]肿瘤防治研究,1999,26(5):330.
[70]杨勤建.化痰散结方含药血清诱导人肺癌细胞凋亡的机理研究.[J]北京中医药大学学报,1999,22(5):70.
[71]李大景,等.榄香烯的药理研究及临床应用.[J]时珍国医国药,2001,12(12):1123.
[72]杨雁,陈敏珠.黄芪总苷对肝癌细胞凋亡及wt-p53基因表达的影响.[J]中国药理学通报,2001,17(4):447.
[73]郭伟剑,等.健脾理气药诱导人肝癌细胞MMC7221凋亡的研究.[J]世界华人消化杂志,2000,8(1):52.
[74]王昌俊,等.中药复方AC960对人肝癌细胞p21、ras、bcl-2、p53基因表达调控作用的研究.[J]中国中医药科技,2000,7(1):10.
[75]张瑾峰,等.抗癌药莪棱舌草1号诱导人肝癌细胞凋亡的研究.[J]首都医科大学学报,2002,23(4):310.
[76]刘坚,等.中药复方搏癌丸对人肝癌细胞周期及bax、bcl-2、p53基因表达调控的影响.[J]中西医结合肝病杂志,2004,14(3):152.
[77]李冬涛,等.益气活血软坚解毒方含药血清诱导人肝癌细胞系BEL-7402细胞凋亡过程中部分凋亡调控基因变化.[J]世界华人消化杂志,2006,14(36):3443.
[78]郑丽兰,许剑琴.中药免疫机理研究进展.[J]动物医学进展,2004,25(6):32.
[79]祖炬雄.论中药与机体免疫的研究概况.[J]中医药信息,1996,2:17.
[80]程晓东,等.中药扶正方对小鼠Lewis肺癌的疗效及其免疫学机理的研究.[J]中国中西医结合杂志,1997,17(2):88.
[81]陈焕朝,等.龙泉复方制剂的抑瘤作用及其作用机制.[J]肿瘤防治研究2006,33(4):255.
[82]许轶琛,等.肺癌舒颗粒剂对Lewis肺癌的作用机理研究.[J]中医药刊,2004,22(12):2248.
[83]朱惠蓉,刘嘉湘.益肺抗瘤饮对Lewis肺癌荷瘤小鼠神经内分泌免疫的实验研究.[J]上海中医药大学学报,2000,14(2):44.
[84]毛海婷,等.淫羊藿甙对人高转移肺癌细胞膜的影响.[J]中药材,1999,22(1):35.
[85] Mochizuki M , et al. Inhibitory effect of tumor metastasis in mice by saponin , ginsenoside-Rb2, 20(R) and 20(S)-ginsenoside-Rg3, of red ginseng.[J] Biol Pharm Bull,1995,18(9):1197.
[86]陈大富,等.裸鼠原位种植人乳腺癌细胞株术后早期应用人参皂甙Rg3对切口愈合的影响.[J]肿瘤防治研究,2003,30(5):391.
[87] Ji Yoon Lee,et al. Antitumor Promotional effects of a novel intestinal bacterial metabolite (IH-901) derived from the protopanaxadiol-type ginsenosides in mouse skin.[J] Carcinogenesis,2005,26(2):359.
[88]倪劲松,等.20(S)-人参皂苷Rg3对Lewis肺癌生长及转移的抑制作用.[J]肿瘤防治研究.2006,33(5)311.
[89]曲婷婷,等.人参皂苷Rb1、Rg1与5-氟脲嘧啶对荷瘤小鼠免疫功能的影响.[J]中医研究,2006,19(5)16.
[90]范元芳,等.四君子汤加味对癌症患者免疫功能的影响——附110例报告.[J]福建中医药,1998,29(3)4.
[91]方乐堃，等．复方小柴胡汤对荷EAC鼠IL-2水平和CD4+/CD8+比值的影响.[J]中国病理生理杂志,2007,23(9)1720.
[92]扬错,等.柴胡乳剂对小鼠免疫功能的影响.[J]沈阳药科大学学报2006,23(3):169.
[93]赵明芳,等.华蟾素对H22荷瘤小鼠肝癌细胞Mg2+-ATP酶、葡萄糖-6-磷酸酶活性的影响.[J]山东医药,2007,47(4):25.
[94]祁鸣,薛京伦.Na+、K+-ATP酶的特性研究及其应用.[J]生物化学与生物物理进展,1986;3:22.
[95] Steknoven FS. Transport adenosine triphosphases properties and function. Physiol Rew 1981; 61 (1):1.
[96]汤雪明.超微结构酶细胞化学技术的建立和应用.[J]细胞生物学杂志,1985; 7:3.
[97]金惠铭.病理生理学.[M]第5版.北京:人民卫生出版社,2001.184-185.
[98]蔡玉文,等.胃癌癌周淋巴细胞酶活性变化与生物学行为关系.[J]实用癌症杂志,1997,12(1):
[99]刘春英,等.肺癌平药物血清对A549人肺癌细胞株Mg2+-ATP、G-6-P酶活性的影响.[J]中国中医药信息杂志,2004,11(11):969.
[1]细胞凋亡的基础与临床.[M]人民卫生出版社2000-7 405.
[2] Kerr JF,Winterford CM,Harmon BV .Apoptosis. Its significance in cancer and cancer therapy. [J] Cancer. Cancer, 1994; 73(8): 2013.
[3] Tessitore L, et al. The role of apoptosis in growing and stationary rat ascites hepatoma. [J] Pathol, 1993; 171(4): 301.
[4] Kong J, Ringer DP. Quantitative in situ image analysis of apoptosis in well and poorly differentiated tumors from rat liver.[J] Am J Pathol, 1995; 147(6): 1626.
[5] Kondo M , et al.Diverse p53 gene aberration in hepatocellula rcarcinoma detected by dual-color fluorescence in situ hybridization [J]. Gastroenterol Hepatol, 2004, 19: 1066.
[6] Lipinsiki KS,et al. Tumour-specific therapeutic adenovirus vectors: repression of transgene expenssion in healthy cells by endogenous p53 . [J] Gene Ther, 2001,8: 274.
[7]黄必军,等.肝细胞癌中p53基因的缺失与HER22基因的扩增及其意义.[J]中华病理学杂志,2003,32(1):20.
[8] Power C,Fanning N,Redmond HP. Cellular apoptosis and organ injury insepsis: a review. Shock, 2002, 18(3): 197.
[9] Shimizu H, Burch LR, Smith AJ, et al. The conformationally flexible S9-S10 linke rregion in the core domain of p5 3contains a novel MDM 2 binding site whose mutation increases ubiquitination of p53 invivo.J Biol Chem, 2002, 277:28446.
[10] Leung KM, et al. The candidate tumor suppressor ING1b can stabilize p53 by disrupting the regulation of p53 by M DM2.Cancer Res, 2002, 62: 4890.
[11] Kataoka H,Bonnefin P,Vieyra D,et al. ING1 represses transcription by direct DNA binding and through effects on p53. Cancer Res, 2003, 3: 5785.
[12] Ltoh T,Shiro T,Seki T, et al. Relationship between P53 overexpression and the proliferation activity in hepatoccllular carcinoma.[J] Int J Mol Med, 2000,6(2): 137.
[13] Xiao EH, et al. Effects of p53 on apoptosis and proliferation of hepatocellular carcinoma cells treated with transcatheter arterial chemoembolization . [J] World J Gastroenterol, 2004, 10 (2): 190.
[14] Brfssac B, et al. Abnormal structore and expression of P53 gene in human hepatoccllular carcinoma [J]. Proc Natl Acad Sci USA, 1990, 87(1): 973
[15]戴益民,等.人肝细胞癌P53异常的预后意义.[J]华人消化杂志, 1998,6(12): 1043.
[16]张建中,等.凋亡调控基因Mcl-1和bcl-2在反应性及肿瘤性淋巴组织中的表达及其意义.[J]肿瘤防治杂志,2002,9(1):22.
[17] CHIU CT, et al. Expression of Bcl-2 family modulatedthrough p53-dependent pathway in hman hepatocel-lularcarcinoma[J].Dig Dis Sci,2003,48(6):670.
[18] Cleary ML, et al. Cloning and structure analysis of cDNA for bcl-2 and hybrid bcl-2 im munoglobulin transcripts resultion from the t(14; 18) translocation [J] Cell, 1986, 47: 19.
[19] Shibata D,et al. Detection of specific t(14;18) chromosomal translocations in fixed tissue [J]. Human Pathol, 1990, 21: 199.
[20] Weiss LM,et al. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas [J]. N Engl J Med, 1987, 317: 1185.
[21] Guo XZ,et al. Effect of bax,bcl-2 and bcl-xl on regulating apoptosis in tissues of normal liver and hepatocellular carcinoma. World J Gastroenterol, 2002, 8(6):1059.
[22] Chang YC, Xu YH. Expression of Bcl-2 inhibited Fas-mediated apoptosis in human hepatocellular carcinoma BEL 7404 cells. Cell Res, 2000, 10 (3): 233.
[23]郭琳琅,肖莎.应用原位杂交技术检测原发性肝癌组织中bcl2基因断裂点.[J]实用癌症杂志,1998,13(4):255.
[24] Nakopoulou L, et al. Bcl-2 protein expression in acule and chroic hepatitis cirrhosis and hepatocellular carcinomal . [J] Pathol Res Prect, 1999, 195(1): 19.
[25]王万忠,等.bcl22癌基因在肝肿瘤表达.[J]中华医学杂志,1996,76(6):470.
[26] Charlotte F, et al. Immunohistochemical detection of bcl-2 protein in normal and patholical human liver[J]. Am J Pathol, 1994, 144: 460.
[27] Fiorentino M, et al. High levels of bcl-2 messenger RNA detected by in siiu hybridization in human hepatocellular and cholangiocellular carcinomas . [J] Diagn Mol Pathol, 1999, 8(4); 189.
[28] Velculescu VE, et al. Analysis of human transcriptomes . [J] Nat GENE,1999, 23(4); 387.
[29] Ikeguchi M,et al. Expression of surviving messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol, 2002,11(1): 33.
[30] Morinaga S, et al. Expression of surviving mRNA associates with apoptosis proliferation and histologically aggressive features in hepatocellular carcinoma. [J] Oncol Rep, 2004, 12(6): 1189.
[31] Sheng-Quan Cheng, et al. Knockdown of Survivin gene expression by RNA induces apoptosis in human hepatocellular carcinoma cell line SMMC-7721 [J]. World J Gastroeritero, 2005, 11(5): 756.
[32] Dahia FI. PTEN, a unique tumor suppressor gene [J]. Endocr Relate Cancer, 2000, 7(2): 115.
[33] Fujiwara Y,et al. PTEN/MMAC 1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinoma [J]. Jpn J Cancer Res , 2000, 91(3): 287.
[34] Yu J, et al. Methylation profiling of twenty promoter CPG island of genes which may contribute to hepatocellular carcinogenesis [J]. BWC Cancer .2002,2(29): 1471.
[35] Zhang L, et al. Study of the PTEN gene expression and FAK phosphorylation in human an hepatocarcinoma tissues and cell lines [J]. Mol Cell Biochem, 2004,262(1-2): 25.
[36] Horie Y, et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepacellular carcinomas [J]. Clin invest 2004, 113(12): 1774.
[37] Yeh KT, et al. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in hepatocellular carcenoma [J]. Cancer Invest ,2000,18(2):123.
[38]郭双平,王丽,王文亮.抑癌基因PTEN在肝癌组织中的突变及其对肝癌细胞增殖和凋亡的调控作用.[J]中华病理学杂志,2006,35(8):467-72
[39] Toschi E, et al.Wild-Type p53 gene transfer inhibits invasion and reduces matrix metalloproteinase-2 levels in p53-mutated human melanoma cells.[J] Invest Dermatol, 2000, 114: 1188.
[40] Tadahisa S, et al.A poptosis induced by adenovirus-mediated p53gene transfer in human glimna correlates with site-specific phosphorylation.Cancer Res, 2002,62: 1069.
[41] Watanabe T, Sullenger BA. Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts.Proc Natl A cad Sci USA, 2000, 97: 8490.
[42] Dai DJ,et al. Survivin antisense compound inhibits proliferation and promotes apoptosis in liver cancer cells. World J Gastroentero1, 2005, 11 ( 2 ): 193.
[43] Cheng SQ, Wang WL, Yan W, et al. Knockdown of survivin gene expression by RNAi induces apoptusis in human hepatocellular carcinoma cell lineSMMC-7721. World J Gastroenterol, 2005, 11 (5): 756.
[44]张晨莉,等.生存素反义核苷酸诱导肝癌细胞株SMMC-7721凋亡和增加其对抗肿瘤药物敏感性的研究.[J]胃肠病学,2003,8(5):269.
[45] Li YX,et al. Wild type p53 increased chemosensitivity of drug-resistant human hepatocellularcar cinoma Bel 7402/5-FU cells [J] .Acta Pharmacol Sin, 2004, 25: 76.
[46]杨晓红,等.外源性p53基因转染的人肝癌细胞化疗药物敏感性的研究.[J]免疫学杂志,2005,21(2):148.
[1] Iwama H.Effect of Shosaikoto, a Japanese and Chinese traditional herbal medicinal mixture on the mitogenic activity of lipopolysaccharide : A new pharmacology testing method . [J] J Ethnopharmacal,1987,211:45.
[2]田代真一.“血清药理学”と“血清药化学”——汉方の药理学かぃ始未つた药物血中浓度测定の新しぃ世界.[J] TDM研究,1988,(5):54.
[3]吴水生,等.血清药理学研究中含药血清是否需灭活的探讨.[J]福建中医学院学报,2001,11(2):45.
[4]张德付.中药血清药理学方法在肿瘤研究中存在的主要问题及对策.[J]中医研究2004,17(5)13.
[5]罗焕敏.关于“血清药理学”与“血浆药理学”.[J]中国药理学通报,2003,19(9):1075.
[6]陆慧晶.血清药理学研究中的若干问题探讨.[J]基层中药杂志,2000,14(3):51.
[7]刘平.关于血清药理学的若干思考.[J]中国中西医结合杂志,1995,19(5):263.
[8]赵万红,等.中药血清学的方法学探讨.[J]中药新药与临床药理,2002,13(2):122.
[9]王力倩,等.血清药理学方法研究探索.[J]中药药理与临床,1997,13(3):29.
[10]杨彦芳,王玉芹.中药复方血清药理学方法规范化探讨.[J]中国中西医结合杂志,2000,20(5):380.
[11]李仪奎.中药血清药理学实验方法的若干问题.[J]中药新药与临床药理,1999,10(2):95.
[12]罗焕敏.关“血清药理学”与“血浆药理学”.[J]中国药理学通报,2003,19(9):1075.
[13]程珠炉,洪浩.中药血清药理学研究方法的几点思考.[J]安徽中医学院学报,2001,20(2):531
[14]王力倩,等用中药血清药理学的方法观察了苦参、仙鹤草的抗肿瘤作用.[J]中国中医药科技,1995,2(5):19.
[15]李秀荣,等.消瘤平移合剂含药血清对肝癌细胞H-7402细胞凋亡的实验研究.[J]中国中西医结合杂志,2001,21(9):684.
[16]王宁生.关于血清药理学的若干思考.[J]中国中西医结合杂志,1999,19(5):263.
[17]孟李,王宁生.含药血清的制备方法研究.[J]中药新药与临床药理,1999,10(5):290.
[18]程珠炉,洪浩.中药血清药理学研究方法几点思考.[J]安徽中医学院学报,2001,20(2):53.
[19]杨奎,等.中药血清药理学方法学研究给药方案的研究.[J]中药药理与临床,1999,15(3):43.
[20]吴健宇,等.补阳还五汤保护自由基损伤血管内皮细胞的血清药理实验方法的建立.[J]中药药理与临床,1999,15(1):4547.
[21]梁春敏,王贤喜,董群,等.玉屏风散对小鼠免疫调节作用的血清药理学研究[J].上海免疫学杂志,2003,23(6):285-287.
[22]孙艳红,等.中药血清药理学方法研究概况.[J]时珍国医国药,2002,13(2):114.
[23]崔晓兰,等.中药复方血清药理研究方法学探讨.[J]中国实验方剂学杂志,1998,4(2):13.
[24] UmedaM,Amagaya S,Oginara. Effect of certain herbal medicines on the biotransformation of arachidonicacid :a new pharmacological testing method using serum [J]. J Ethnopharmacol,1988,23 (1) :91.
[25]张英华,等.当归补血汤及其含药血清对小鼠红系造血祖细胞克隆的影响.[J]中国实验方剂学杂志,1999,5(4):33.
[26]周明眉,等.中药血清药理学的方法学研究--反应体系中含药血清加入量的研究.[J]中药药理与临床,1998,14(6):43.
[27]张良,等.中药血清药理学方法研究进展.[J]南京中医药大学学报,2002,18(4):254.
[28]王国佐.血清药理学方法在中药研究中的进展.[J]湖南中医药大学学报,2007,27(3):78.
[29]于海荣,等.血清药理学方法研究进展.[J]承德医学院学报, 2006,23(2)183.
[30]黄席,等.“复方效应成分动力学”新假说:科学证据、要素及意义.[J]中国中药杂志,1997,22(4)250.
[2]田代真一.“血清药理学”と“血清药化学”——汉方の药理学かぃ始まつた药物血中浓度测定の新しぃ世界.TDM研究,1988;(5):54.
[3]吴水生,等.血清药理学研究中含药血清是否需灭活的探讨.[J]福建中医学院学报,2001,11(2):45.
[4]张德付.中药血清药理学方法在肿瘤研究中存在的主要问题及对策.[J]中医研究,2004,17(5)13.
[5]罗焕敏.关于“血清药理学”与“血浆药理学”.[J]中国药理学通报,2003,19(9):1075.
[6]陆慧晶.血清药理学研究中的若干问题探讨.[J]基层中药杂志,2000,14(3):51.
[7]刘平.关于血清药理学的若干思考.[J]中国中西医结合杂志,1995,19(5):263.
[8]王力倩,等.血清药理学方法研究探索.[J]中药药理与临床,1997,13(3):29.
[9]杨彦芳,王玉芹.中药复方血清药理学方法规范化探讨.[J]中国中西医结合杂志,2000,20(5):380.
[10]李仪奎.中药血清药理学实验方法的若干问题.[J]药新药与临床药理,1999,10(5):263.
[11]罗焕敏.关于“血清药理学”与“血浆药理学”.[J]中国药理学通报,2003,19(9):1075.
[12]程珠炉,洪浩.中药血清药理学研究方法的几点思考.[J]安徽中医学院学报,2001,20(2):531.
[13]王力倩,等.用中药血清药理学的方法观察苦参、仙鹤草的抗肿瘤作用.[J]中国中医药科技,1995,2(5):19.
[14]李秀荣,等.消瘤平移合剂含药血清对肝癌细胞H-7402细胞凋亡的实验研究.[J]中国中西医结合杂志,2001,21(9):684.
[15]王宁生.关于血清药理学的若干思考.[J]中国中西医结合杂志,1999,19(5):263.
[16]孟李,王宁生.含药血清的制备方法研究.[J]中药新药与临床药理,1999,10(5):290.
[17]程珠炉,洪浩.中药血清药理学研究方法几点思考.[J]安徽中医学院学报,2001,20(2):53.
[18]崔晓兰,等.中药复方血清药理研究方法学探讨.[J]中国实验方剂学杂志,1998,4(2):13.
[19]杨奎,等.中药血清药理学方法学研究给药方案的研究.[J]中药药理与临床,1999,15(3):43.
[20]吴健宇,等.补阳还五汤保护自由基损伤血管内皮细胞的血清药理实验方法的建立.[J]中药药理与临床,1999,15(1):4547.
[21] Srehan P,et al. New eolorimetric cytotoxicity assay for auticaneer-drug screening J of Nat Cancer Ins. 1990,82(13):1107.
[22]王青素,等.SRB显色法用于抗癌药物敏感性实验的研究.[J]科技通报,2000,16(2):104.
[23] Mosmann T. Rapid Colorimetric Assay for cellular Growth and Survival; Applecation to Proliferation and Cytotoxcity Assays .[J] Immunol Methods ,1983,65:55.
[24]李杰,刘玉琴.MTT法在肿瘤研究中的改良及应用进展.[J]中国肿瘤临床,1998,25(4):312.
[25]朱寿兴,等.肿瘤细胞体外药物敏感实验MTT法在实体肿瘤中的应用.[J]华西药学杂志,1998,13(3):154.
[26]曾庆华,等.MTT测定恶性肿瘤细胞对化疗药物敏感性.[J]中国普通外科杂志.2000,9(6):552.
[27] Tim Oo Khor,et al. Positive correlation between overexpression of phospho-BAD with phosphorylated Akt at Serine 473 but not threoning 308 in colorectal carcinoma. Cancer Letters,2004,210:139.
[28] Daveau M,et al. Hepatocyte growth factor;transforming growth factor alpha,and their receptors as combined markers of prognosis in hepatocellular carcinoma. [J] Mol Carcinog,2003,36(3):130.
[29]梁重峰,潘立群.中医药调控肿瘤细胞凋亡的研究进展.[J]甘肃中药,2005,18(3):47.
[30] Yano H,et al. The herbel medicine sho saikoto inbibit sprolifertion of cancer celling by inducing apolosis and arest at the G0/G1 phase. [J] Cancer Res,1994,54(2):448.
[31]孙震晓,等.去甲斑蝥素诱导人肝癌细胞的影响.[J]临床肝胆病杂志,1999,30(1):65.
[32]邸雅南,等.刺五加叶皂苷对肝癌细胞的影响[J] .临床肝胆病杂志,2000,6(2):104.
[33]杨雁,陈敏珠.黄芪总提取物诱导肝癌细胞凋亡及其作用机理.[J]中国药理学会通讯,2000,17(4):16.
[34]汤利华,等.槲皮素对肝癌HepG2细胞生长影响的体外研究.[J]中国药业,2007,16(15)11.
[35]樊光华,等.人参皂甙-Rh2诱导人肝癌Bel-7404细胞凋亡的作用.[J]实用癌症杂志,2003,18(1):16.
[36]钟志宏,等.丹参酮ⅡA抑制HepG2细胞生长及诱导其凋亡的实验研究.[J]中南大学学报,2007,32(1):99.
[37]徐学军,等.B-榄香烯诱导人肝癌细胞珠7721凋亡的研究.[J]第三军医大学学报,1999,21(4):268.
[38]刘剑伦,等.康莱特注射液诱导人肝癌细胞凋亡的研究.[J]实用癌症杂志,2001,16(4):343.
[39]邵红莲,等.大蒜素诱导人肝癌7402细胞凋亡.[J]解剖学报,2001,32(3):290.
[40]张天娥,等.鹤莲克癌灵对肝癌H22细胞周期及细胞凋亡的影响.[J]成都中医药大学学报,1999,9(5):25.
[41]韩克起,黄传继.扶正抗癌方对大鼠移植性肝癌病理形态及超微结构的影响.[J]中西医结合肝病杂志,1999,9(5):25.
[42]张丽红,等.益肠泰诱导CCL229人大肠癌细胞凋亡的形态学研究.[J]中国基层医药,2007,14(6):974.
[43] Shimizu H,et al. The conformationally flexible S9-S10 linke rregion in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 invivo. [J] Biol Chem,2002,277:28446.
[44] Leung KM,et al. The candidate tumor suppressor ING1b can stabilize p53 by disrupting the regulation of p53 by MDM2. Cancer Res,2002,62:4890.
[45] Kataoka H,et al. ING1 represses transcription by direct DNA binding and through effects on p53. Cancer Res,2003,3:5785.
[46] Power C,et al. Cellular apoptosis and organ injury insepsis:a review. Shock,2002,18(3): 197.
[47] Hainaut P,Pfeifer GP. Pattems of p53 G-T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. [J] Carcinogenesis,2001,22(3):367.
[48] Ltoh T,et al. Relationship between p53 overexpression and the proliferation activity in hepatoccllular carcinoma. [J] Int J Mol Med,2000,6(2):137.
[49] Xiao EH,et al. Effects of p53 on apoptosis and proliferation of hepatocellular carcinoma cells treated with transcatheter arterial chemoembolization. World J Gastroenterol, 2004,10(2):190.
[50] Brfssac B,et al. Abnormal structore and expression of p53 gene in human hepatoccllular carcinoma. [J] Proc Natl Acad Sci USA,1990,87(1):973.
[51] Kigawa J,et al. Effect of p53 gene transfer and cisplatin in a peritonit is carcinomatosa model with p53 deficient ovarian cancer cells. [J] Gynecol Oncol,2002,84(2):210.
[52] Shinoura N,et al. Cotransduction of Apafand caspase-9 highly enhances p53-mediated apoptosis in gliomas. [J] Br J Cancer,2002,86(4):587.
[53]张建中,等.凋亡调控基因Mcl-1和bcl-2在反应性及肿瘤性淋巴组织中的表达及其意义.[J]肿瘤防治杂志,2002,9(1):22-24,29.
[54] Chiu CT,et al. Expression of Bcl-2 family modulated through p53-dependent pathway in human hepatocel-lular carcinoma. [J] Dig Dis Sci,2003,48(6):670.
[55] Cleary ML,et al. Cloning and structure analysis of cDNA for bcl-2 and hybrid bcl-2 immunoglobulin transcripts resultion from the t(14;18) translocation . [J] Cell,1986,47:19.
[56] Shibata D,et al. Detection of specific t(14;18) chromosomal translocations in fixed tissue. [J] Human Pathol,1990,21:199.
[57] Weiss LM,et al. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. [J] N Engl J Med,1987,317:1185.
[58] Guo XZ,et al. Effect of bax,bcl-2 and bcl-xl on regulating apoptosis in tissues of normal liver and hepatocellular carcinoma. World J Gastroenterol,2002,8(6):1059.
[59] Chang YC,Xu YH. Expression of Bcl-2 inhibited Fas-mediated apoptosis in human hepatocellular carcinoma BEL-7404 cells. Cell Res,2000,10(3):233.
[60]郭琳琅,肖莎.应用原位杂交技术检测原发性肝癌组织中bcl-2基因断裂点.[J]实用癌症杂志,1998,13(4):255.
[61] Nakopoulou L,et al. Bcl-2 protein expression in acule and chroic hepatitis cirrhosis and hepatocellular carcinomal. [J] Pathol Res Prect,1999,195(1):19.
[62]王万忠,等.Bcl-2癌基因在肝肿瘤表达.[J]中华医学杂志,1996,76(6):470.
[63] Charlotte F,et al. Immunohistochemical detection of bcl-2 protein in normal and patholical human liver. [J] Am J Pathol,1994,144:460.
[64] Fiorentino M,et al. High levels of bcl-2 messenger RNA detected by in siiu hybridization in human hepatocellular and cholangiocellular carcinomas. [J] Diagn Mol Pathol,1999,8(4);189.
[65] Toschi E , et al. Wild-Type p53 gene transfer inhibits invasion and reduces matrix metalloproteinase-2 levels in p53-mutated human melanoma cells. [J] Invest Dermatol,2000,114:1188.
[66] Tadahisa S,et al. A poptosis induced by adenovirus-mediated p53 gene transfer in human glimna correlates with site-specific phosphorylation. [J] Cancer Res,2002,62:1069.
[67] Watanabe T,Sullenger BA. Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. Proc Natl Acid Sci USA,2000,97:8490.
[68]袁静.檞皮素抗肿瘤作用研究进展.[J]国外医学中医中药分册,1996,18(5):3.
[69]黄培春.中药复方“冬夏丸”体外对6株人肿瘤细胞系作用的研究.[J]肿瘤防治研究,1999,26(5):330.
[70]杨勤建.化痰散结方含药血清诱导人肺癌细胞凋亡的机理研究.[J]北京中医药大学学报,1999,22(5):70.
[71]李大景,等.榄香烯的药理研究及临床应用.[J]时珍国医国药,2001,12(12):1123.
[72]杨雁,陈敏珠.黄芪总苷对肝癌细胞凋亡及wt-p53基因表达的影响.[J]中国药理学通报,2001,17(4):447.
[73]郭伟剑,等.健脾理气药诱导人肝癌细胞MMC7221凋亡的研究.[J]世界华人消化杂志,2000,8(1):52.
[74]王昌俊,等.中药复方AC960对人肝癌细胞p21、ras、bcl-2、p53基因表达调控作用的研究.[J]中国中医药科技,2000,7(1):10.
[75]张瑾峰,等.抗癌药莪棱舌草1号诱导人肝癌细胞凋亡的研究.[J]首都医科大学学报,2002,23(4):310.
[76]刘坚,等.中药复方搏癌丸对人肝癌细胞周期及bax、bcl-2、p53基因表达调控的影响.[J]中西医结合肝病杂志,2004,14(3):152.
[77]李冬涛,等.益气活血软坚解毒方含药血清诱导人肝癌细胞系BEL-7402细胞凋亡过程中部分凋亡调控基因变化.[J]世界华人消化杂志,2006,14(36):3443.
[78]郑丽兰,许剑琴.中药免疫机理研究进展.[J]动物医学进展,2004,25(6):32.
[79]祖炬雄.论中药与机体免疫的研究概况.[J]中医药信息,1996,2:17.
[80]程晓东,等.中药扶正方对小鼠Lewis肺癌的疗效及其免疫学机理的研究.[J]中国中西医结合杂志,1997,17(2):88.
[81]陈焕朝,等.龙泉复方制剂的抑瘤作用及其作用机制.[J]肿瘤防治研究2006,33(4):255.
[82]许轶琛,等.肺癌舒颗粒剂对Lewis肺癌的作用机理研究.[J]中医药刊,2004,22(12):2248.
[83]朱惠蓉,刘嘉湘.益肺抗瘤饮对Lewis肺癌荷瘤小鼠神经内分泌免疫的实验研究.[J]上海中医药大学学报,2000,14(2):44.
[84]毛海婷,等.淫羊藿甙对人高转移肺癌细胞膜的影响.[J]中药材,1999,22(1):35.
[85] Mochizuki M , et al. Inhibitory effect of tumor metastasis in mice by saponin , ginsenoside-Rb2, 20(R) and 20(S)-ginsenoside-Rg3, of red ginseng.[J] Biol Pharm Bull,1995,18(9):1197.
[86]陈大富,等.裸鼠原位种植人乳腺癌细胞株术后早期应用人参皂甙Rg3对切口愈合的影响.[J]肿瘤防治研究,2003,30(5):391.
[87] Ji Yoon Lee,et al. Antitumor Promotional effects of a novel intestinal bacterial metabolite (IH-901) derived from the protopanaxadiol-type ginsenosides in mouse skin.[J] Carcinogenesis,2005,26(2):359.
[88]倪劲松,等.20(S)-人参皂苷Rg3对Lewis肺癌生长及转移的抑制作用.[J]肿瘤防治研究.2006,33(5)311.
[89]曲婷婷,等.人参皂苷Rb1、Rg1与5-氟脲嘧啶对荷瘤小鼠免疫功能的影响.[J]中医研究,2006,19(5)16.
[90]范元芳,等.四君子汤加味对癌症患者免疫功能的影响——附110例报告.[J]福建中医药,1998,29(3)4.
[91]方乐堃，等．复方小柴胡汤对荷EAC鼠IL-2水平和CD4+/CD8+比值的影响.[J]中国病理生理杂志,2007,23(9)1720.
[92]扬错,等.柴胡乳剂对小鼠免疫功能的影响.[J]沈阳药科大学学报2006,23(3):169.
[93]赵明芳,等.华蟾素对H22荷瘤小鼠肝癌细胞Mg2+-ATP酶、葡萄糖-6-磷酸酶活性的影响.[J]山东医药,2007,47(4):25.
[94]祁鸣,薛京伦.Na+、K+-ATP酶的特性研究及其应用.[J]生物化学与生物物理进展,1986;3:22.
[95] Steknoven FS. Transport adenosine triphosphases properties and function. Physiol Rew 1981; 61 (1):1.
[96]汤雪明.超微结构酶细胞化学技术的建立和应用.[J]细胞生物学杂志,1985; 7:3.
[97]金惠铭.病理生理学.[M]第5版.北京:人民卫生出版社,2001.184-185.
[98]蔡玉文,等.胃癌癌周淋巴细胞酶活性变化与生物学行为关系.[J]实用癌症杂志,1997,12(1):
[99]刘春英,等.肺癌平药物血清对A549人肺癌细胞株Mg2+-ATP、G-6-P酶活性的影响.[J]中国中医药信息杂志,2004,11(11):969.
[1]细胞凋亡的基础与临床.[M]人民卫生出版社2000-7 405.
[2] Kerr JF,Winterford CM,Harmon BV .Apoptosis. Its significance in cancer and cancer therapy. [J] Cancer. Cancer, 1994; 73(8): 2013.
[3] Tessitore L, et al. The role of apoptosis in growing and stationary rat ascites hepatoma. [J] Pathol, 1993; 171(4): 301.
[4] Kong J, Ringer DP. Quantitative in situ image analysis of apoptosis in well and poorly differentiated tumors from rat liver.[J] Am J Pathol, 1995; 147(6): 1626.
[5] Kondo M , et al.Diverse p53 gene aberration in hepatocellula rcarcinoma detected by dual-color fluorescence in situ hybridization [J]. Gastroenterol Hepatol, 2004, 19: 1066.
[6] Lipinsiki KS,et al. Tumour-specific therapeutic adenovirus vectors: repression of transgene expenssion in healthy cells by endogenous p53 . [J] Gene Ther, 2001,8: 274.
[7]黄必军,等.肝细胞癌中p53基因的缺失与HER22基因的扩增及其意义.[J]中华病理学杂志,2003,32(1):20.
[8] Power C,Fanning N,Redmond HP. Cellular apoptosis and organ injury insepsis: a review. Shock, 2002, 18(3): 197.
[9] Shimizu H, Burch LR, Smith AJ, et al. The conformationally flexible S9-S10 linke rregion in the core domain of p5 3contains a novel MDM 2 binding site whose mutation increases ubiquitination of p53 invivo.J Biol Chem, 2002, 277:28446.
[10] Leung KM, et al. The candidate tumor suppressor ING1b can stabilize p53 by disrupting the regulation of p53 by M DM2.Cancer Res, 2002, 62: 4890.
[11] Kataoka H,Bonnefin P,Vieyra D,et al. ING1 represses transcription by direct DNA binding and through effects on p53. Cancer Res, 2003, 3: 5785.
[12] Ltoh T,Shiro T,Seki T, et al. Relationship between P53 overexpression and the proliferation activity in hepatoccllular carcinoma.[J] Int J Mol Med, 2000,6(2): 137.
[13] Xiao EH, et al. Effects of p53 on apoptosis and proliferation of hepatocellular carcinoma cells treated with transcatheter arterial chemoembolization . [J] World J Gastroenterol, 2004, 10 (2): 190.
[14] Brfssac B, et al. Abnormal structore and expression of P53 gene in human hepatoccllular carcinoma [J]. Proc Natl Acad Sci USA, 1990, 87(1): 973
[15]戴益民,等.人肝细胞癌P53异常的预后意义.[J]华人消化杂志, 1998,6(12): 1043.
[16]张建中,等.凋亡调控基因Mcl-1和bcl-2在反应性及肿瘤性淋巴组织中的表达及其意义.[J]肿瘤防治杂志,2002,9(1):22.
[17] CHIU CT, et al. Expression of Bcl-2 family modulatedthrough p53-dependent pathway in hman hepatocel-lularcarcinoma[J].Dig Dis Sci,2003,48(6):670.
[18] Cleary ML, et al. Cloning and structure analysis of cDNA for bcl-2 and hybrid bcl-2 im munoglobulin transcripts resultion from the t(14; 18) translocation [J] Cell, 1986, 47: 19.
[19] Shibata D,et al. Detection of specific t(14;18) chromosomal translocations in fixed tissue [J]. Human Pathol, 1990, 21: 199.
[20] Weiss LM,et al. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas [J]. N Engl J Med, 1987, 317: 1185.
[21] Guo XZ,et al. Effect of bax,bcl-2 and bcl-xl on regulating apoptosis in tissues of normal liver and hepatocellular carcinoma. World J Gastroenterol, 2002, 8(6):1059.
[22] Chang YC, Xu YH. Expression of Bcl-2 inhibited Fas-mediated apoptosis in human hepatocellular carcinoma BEL 7404 cells. Cell Res, 2000, 10 (3): 233.
[23]郭琳琅,肖莎.应用原位杂交技术检测原发性肝癌组织中bcl2基因断裂点.[J]实用癌症杂志,1998,13(4):255.
[24] Nakopoulou L, et al. Bcl-2 protein expression in acule and chroic hepatitis cirrhosis and hepatocellular carcinomal . [J] Pathol Res Prect, 1999, 195(1): 19.
[25]王万忠,等.bcl22癌基因在肝肿瘤表达.[J]中华医学杂志,1996,76(6):470.
[26] Charlotte F, et al. Immunohistochemical detection of bcl-2 protein in normal and patholical human liver[J]. Am J Pathol, 1994, 144: 460.
[27] Fiorentino M, et al. High levels of bcl-2 messenger RNA detected by in siiu hybridization in human hepatocellular and cholangiocellular carcinomas . [J] Diagn Mol Pathol, 1999, 8(4); 189.
[28] Velculescu VE, et al. Analysis of human transcriptomes . [J] Nat GENE,1999, 23(4); 387.
[29] Ikeguchi M,et al. Expression of surviving messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol, 2002,11(1): 33.
[30] Morinaga S, et al. Expression of surviving mRNA associates with apoptosis proliferation and histologically aggressive features in hepatocellular carcinoma. [J] Oncol Rep, 2004, 12(6): 1189.
[31] Sheng-Quan Cheng, et al. Knockdown of Survivin gene expression by RNA induces apoptosis in human hepatocellular carcinoma cell line SMMC-7721 [J]. World J Gastroeritero, 2005, 11(5): 756.
[32] Dahia FI. PTEN, a unique tumor suppressor gene [J]. Endocr Relate Cancer, 2000, 7(2): 115.
[33] Fujiwara Y,et al. PTEN/MMAC 1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinoma [J]. Jpn J Cancer Res , 2000, 91(3): 287.
[34] Yu J, et al. Methylation profiling of twenty promoter CPG island of genes which may contribute to hepatocellular carcinogenesis [J]. BWC Cancer .2002,2(29): 1471.
[35] Zhang L, et al. Study of the PTEN gene expression and FAK phosphorylation in human an hepatocarcinoma tissues and cell lines [J]. Mol Cell Biochem, 2004,262(1-2): 25.
[36] Horie Y, et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepacellular carcinomas [J]. Clin invest 2004, 113(12): 1774.
[37] Yeh KT, et al. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in hepatocellular carcenoma [J]. Cancer Invest ,2000,18(2):123.
[38]郭双平,王丽,王文亮.抑癌基因PTEN在肝癌组织中的突变及其对肝癌细胞增殖和凋亡的调控作用.[J]中华病理学杂志,2006,35(8):467-72
[39] Toschi E, et al.Wild-Type p53 gene transfer inhibits invasion and reduces matrix metalloproteinase-2 levels in p53-mutated human melanoma cells.[J] Invest Dermatol, 2000, 114: 1188.
[40] Tadahisa S, et al.A poptosis induced by adenovirus-mediated p53gene transfer in human glimna correlates with site-specific phosphorylation.Cancer Res, 2002,62: 1069.
[41] Watanabe T, Sullenger BA. Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts.Proc Natl A cad Sci USA, 2000, 97: 8490.
[42] Dai DJ,et al. Survivin antisense compound inhibits proliferation and promotes apoptosis in liver cancer cells. World J Gastroentero1, 2005, 11 ( 2 ): 193.
[43] Cheng SQ, Wang WL, Yan W, et al. Knockdown of survivin gene expression by RNAi induces apoptusis in human hepatocellular carcinoma cell lineSMMC-7721. World J Gastroenterol, 2005, 11 (5): 756.
[44]张晨莉,等.生存素反义核苷酸诱导肝癌细胞株SMMC-7721凋亡和增加其对抗肿瘤药物敏感性的研究.[J]胃肠病学,2003,8(5):269.
[45] Li YX,et al. Wild type p53 increased chemosensitivity of drug-resistant human hepatocellularcar cinoma Bel 7402/5-FU cells [J] .Acta Pharmacol Sin, 2004, 25: 76.
[46]杨晓红,等.外源性p53基因转染的人肝癌细胞化疗药物敏感性的研究.[J]免疫学杂志,2005,21(2):148.
[1] Iwama H.Effect of Shosaikoto, a Japanese and Chinese traditional herbal medicinal mixture on the mitogenic activity of lipopolysaccharide : A new pharmacology testing method . [J] J Ethnopharmacal,1987,211:45.
[2]田代真一.“血清药理学”と“血清药化学”——汉方の药理学かぃ始未つた药物血中浓度测定の新しぃ世界.[J] TDM研究,1988,(5):54.
[3]吴水生,等.血清药理学研究中含药血清是否需灭活的探讨.[J]福建中医学院学报,2001,11(2):45.
[4]张德付.中药血清药理学方法在肿瘤研究中存在的主要问题及对策.[J]中医研究2004,17(5)13.
[5]罗焕敏.关于“血清药理学”与“血浆药理学”.[J]中国药理学通报,2003,19(9):1075.
[6]陆慧晶.血清药理学研究中的若干问题探讨.[J]基层中药杂志,2000,14(3):51.
[7]刘平.关于血清药理学的若干思考.[J]中国中西医结合杂志,1995,19(5):263.
[8]赵万红,等.中药血清学的方法学探讨.[J]中药新药与临床药理,2002,13(2):122.
[9]王力倩,等.血清药理学方法研究探索.[J]中药药理与临床,1997,13(3):29.
[10]杨彦芳,王玉芹.中药复方血清药理学方法规范化探讨.[J]中国中西医结合杂志,2000,20(5):380.
[11]李仪奎.中药血清药理学实验方法的若干问题.[J]中药新药与临床药理,1999,10(2):95.
[12]罗焕敏.关“血清药理学”与“血浆药理学”.[J]中国药理学通报,2003,19(9):1075.
[13]程珠炉,洪浩.中药血清药理学研究方法的几点思考.[J]安徽中医学院学报,2001,20(2):531
[14]王力倩,等用中药血清药理学的方法观察了苦参、仙鹤草的抗肿瘤作用.[J]中国中医药科技,1995,2(5):19.
[15]李秀荣,等.消瘤平移合剂含药血清对肝癌细胞H-7402细胞凋亡的实验研究.[J]中国中西医结合杂志,2001,21(9):684.
[16]王宁生.关于血清药理学的若干思考.[J]中国中西医结合杂志,1999,19(5):263.
[17]孟李,王宁生.含药血清的制备方法研究.[J]中药新药与临床药理,1999,10(5):290.
[18]程珠炉,洪浩.中药血清药理学研究方法几点思考.[J]安徽中医学院学报,2001,20(2):53.
[19]杨奎,等.中药血清药理学方法学研究给药方案的研究.[J]中药药理与临床,1999,15(3):43.
[20]吴健宇,等.补阳还五汤保护自由基损伤血管内皮细胞的血清药理实验方法的建立.[J]中药药理与临床,1999,15(1):4547.
[21]梁春敏,王贤喜,董群,等.玉屏风散对小鼠免疫调节作用的血清药理学研究[J].上海免疫学杂志,2003,23(6):285-287.
[22]孙艳红,等.中药血清药理学方法研究概况.[J]时珍国医国药,2002,13(2):114.
[23]崔晓兰,等.中药复方血清药理研究方法学探讨.[J]中国实验方剂学杂志,1998,4(2):13.
[24] UmedaM,Amagaya S,Oginara. Effect of certain herbal medicines on the biotransformation of arachidonicacid :a new pharmacological testing method using serum [J]. J Ethnopharmacol,1988,23 (1) :91.
[25]张英华,等.当归补血汤及其含药血清对小鼠红系造血祖细胞克隆的影响.[J]中国实验方剂学杂志,1999,5(4):33.
[26]周明眉,等.中药血清药理学的方法学研究--反应体系中含药血清加入量的研究.[J]中药药理与临床,1998,14(6):43.
[27]张良,等.中药血清药理学方法研究进展.[J]南京中医药大学学报,2002,18(4):254.
[28]王国佐.血清药理学方法在中药研究中的进展.[J]湖南中医药大学学报,2007,27(3):78.
[29]于海荣,等.血清药理学方法研究进展.[J]承德医学院学报, 2006,23(2)183.
[30]黄席,等.“复方效应成分动力学”新假说:科学证据、要素及意义.[J]中国中药杂志,1997,22(4)250.